Concomitant vascular reconstruction during pancreatectomy for malignant disease: A propensity score-adjusted, population-based trend analysis involving 10 206 patients

JAMA Surgery

Volumn 148, Issue 4, 2013, Pages 331-338

  Worni, Mathias ^a,b   Castleberry, Anthony W ^a   Clary, Bryan M ^a   Gloor, Beat ^b   Carvalho, Elias ^a   Jacobs, Danny O ^a   Pietrobon, Ricardo ^a   Scarborough, John E ^a   White, Rebekah R ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF BERN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE PANCREATITIS; ADULT; ADVERSE OUTCOME; ARTICLE; CARDIOVASCULAR DISEASE; FEMALE; FOREIGN BODY; GASTROINTESTINAL DISEASE; HUMAN; KIDNEY DISEASE; LENGTH OF STAY; LUNG DISEASE; MAJOR CLINICAL STUDY; MALE; PANCREAS CANCER; PANCREAS RESECTION; PEROPERATIVE COMPLICATION; POSTOPERATIVE COMPLICATION; POSTOPERATIVE INFECTION; PRIORITY JOURNAL; SURGICAL MORTALITY; SYSTEMIC DISEASE; TREATMENT OUTCOME; URINARY TRACT DISEASE; VASCULAR SURGERY; WOUND COMPLICATION;

ADENOCARCINOMA; AGED; CHI-SQUARE DISTRIBUTION; COMORBIDITY; DIAGNOSIS-RELATED GROUPS; FEMALE; HOSPITAL MORTALITY; HUMANS; LENGTH OF STAY; LOGISTIC MODELS; MALE; MIDDLE AGED; PANCREAS; PANCREATECTOMY; PANCREATIC NEOPLASMS; POSTOPERATIVE COMPLICATIONS; PROPENSITY SCORE; RECONSTRUCTIVE SURGICAL PROCEDURES; TREATMENT OUTCOME; UNITED STATES; VASCULAR SURGICAL PROCEDURES;

EID: 84876782328     PISSN: 21686254     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamasurg.2013.1058     Document Type: Article

References (37)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012; 62(1):10-29.
2. Oettle H, Post S, Neuhaus P, et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA. 2007;297(3):267-277.
3. Neoptolemos JP, Stocken DD, Bassi C, et al European Study Group for Pancreatic Cancer. Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. JAMA. 2010;304(10):1073-1081.
4. Wagner M, Redaelli C, Lietz M, Seiler CA, Friess H, Bǔchler MW. Curative resection is the single most important factor determining outcome in patients with pancreatic adenocarcinoma. Br J Surg. 2004;91(5):586-594.
5. Herman JM, Swartz MJ, Hsu CC, et al. Analysis of fluorouracil-based adjuvant chemotherapy and radiation after pancreaticoduodenectomy for ductal adenocarcinoma of the pancreas: results of a large, prospectively collected database at the Johns Hopkins Hospital. J Clin Oncol. 2008;26(21):3503-3510.
6. You DD, Lee HG, Heo JS, Choi SH, Choi DW. Prognostic factors and adjuvant chemoradiation therapy after pancreaticoduodenectomy for pancreatic adenocarcinoma. J Gastrointest Surg. 2009;13(9):1699-1706.
7. Lim JE, Chien MW, Earle CC. Prognostic factors following curative resection for pancreatic adenocarcinoma: a population-based, linked database analysis of 396 patients. Ann Surg. 2003;237(1):74-85.
8. Corsini MM, Miller RC, Haddock MG, et al. Adjuvant radiotherapy and chemotherapy for pancreatic carcinoma: the Mayo Clinic experience (1975-2005). J Clin Oncol. 2008;26(21):3511-3516.
9. Riediger H, Keck T, Wellner U, et al. The lymph node ratio is the strongest prognostic factor after resection of pancreatic cancer. J Gastrointest Surg. 2009; 13(7):1337-1344.
10. National Comprehensive Cancer Network. National Comprehensive Cancer Network website. http://www.nccn.org/index.asp. Accessed August 12, 2012.
11. Moore GE, Sako Y, Thomas LB. Radical pancreatoduodenectomy with resection and reanastomosis of the superior mesenteric vein. Surgery. 1951;30(3):550-553.
12. Yekebas EF, Bogoevski D, Cataldegirmen G, et al. En bloc vascular resection for locally advanced pancreatic malignancies infiltrating major blood vessels: perioperative outcome and long-term survival in 136 patients. Ann Surg. 2008; 247(2):300-309.
13. Bachellier P, Rosso E, Lucescu I, et al. Is the need for an arterial resection a contraindication to pancreatic resection for locally advanced pancreatic adenocarcinomǎ a case-matched controlled study. J Surg Oncol. 2011;103(1):75-84.
14. Fukuda S, Oussoultzoglou E, Bachellier P, et al. Significance of the depth of portal vein wall invasion after curative resection for pancreatic adenocarcinoma. Arch Surg. 2007;142(2):172-179, discussion 180.
15. Martin RC II, Scoggins CR, Egnatashvili V, Staley CA, McMasters KM, Kooby DA. Arterial and venous resection for pancreatic adenocarcinoma: operative and long-term outcomes. Arch Surg. 2009;144(2):154-159.
16. Tseng JF, Raut CP, Lee JE, et al. Pancreaticoduodenectomy with vascular resection: margin status and survival duration. J Gastrointest Surg. 2004;8(8): 935-949; discussion 949-950.
17. Turley RS, Peterson K, Barbas AS, et al. Vascular surgery collaboration during pancreaticoduodenectomy with vascular reconstruction. Ann Vasc Surg. 2012; 26(5):685-692.
18. Healthcare Cost and Utilization Project. Overview of the Nationwide Inpatient Sample (NIS). http://www.hcup-us.ahrq.gov/nisoverview.jsp. Accessed August 12, 2012.
19. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45(6):613-619.
20. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373-383.
21. Cleves MA, Sanchez N, Draheim M. Evaluation of two competing methods for calculating Charlson's Comorbidity Index when analyzing short-term mortality using administrative data. J Clin Epidemiol. 1997;50(8):903-908.
22. Guller U, Hervey S, Purves H, et al. Laparoscopic versus open appendectomy: outcomes comparison based on a large administrative database. Ann Surg. 2004; 239(1):43-52.
23. Hu JC, Gu X, Lipsitz SR, et al. Comparative effectiveness of minimally invasive vs open radical prostatectomy. JAMA. 2009;302(14):1557-1564.
24. Rutten-van Mǒlken MP, van Doorslaer EK, van Vliet RC. Statistical analysis of cost outcomes in a randomized controlled clinical trial. Health Econ. 1994; 3(5):333-345.
25. Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika. 1983;70(1):41-55. doi:10.2307/2335942.
26. Brookhart MA, Schneeweiss S, Rothman KJ, Glynn RJ, Avorn J, Stǔrmer T. Variable selection for propensity score models. Am J Epidemiol. 2006;163 (12):1149-1156.
27. Banz VM, Croagh D, Coldham C, et al. Factors influencing outcome in patients undergoing portal vein resection for adenocarcinoma of the pancreas. Eur J Surg Oncol. 2012;38(1):72-79.
28. Riediger H, Makowiec F, Fischer E, Adam U, Hopt UT. Postoperative morbidity and long-term survival after pancreaticoduodenectomy with superiormesentericoportal vein resection. J Gastrointest Surg. 2006;10(8):1106-1115.
29. Hartel M, Niedergethmann M, Farag-Soliman M, et al. Benefit of venous resection for ductal adenocarcinoma of the pancreatic head. Eur J Surg. 2002;168 (12):707-712.
30. Capussotti L, Massucco P, Ribero D, Viganò L, Muratore A, Calgaro M. Extended lymphadenectomy and vein resection for pancreatic head cancer: outcomes and implications for therapy. Arch Surg. 2003;138(12):1316-1322.
31. Harrison LE, Klimstra DS, Brennan MF. Isolated portal vein involvement in pancreatic adenocarcinoma: a contraindication for resection? Ann Surg. 1996; 224(3):342-347, discussion 347-349.
32. Mollberg N, Rahbari NN, Koch M, et al. Arterial resection during pancreatectomy for pancreatic cancer: a systematic review and meta-analysis. Ann Surg. 2011;254(6):882-893.
33. Castleberry AW, White RR, De La Fuente SG, et al. The impact of vascular resection on early postoperative outcomes after pancreaticoduodenectomy: an analysis of the American College of Surgeons National Surgical Quality Improvement Program database [published online August 30, 2012]. Ann Surg Oncol. doi:10 1245/s10434-012-2585-y.
34. Bilimoria KY, Bentrem DJ, Ko CY, Stewart AK, Winchester DP, Talamonti MS. National failure to operate on early stage pancreatic cancer. Ann Surg. 2007; 246(2):173-180.
35. Riall TS, Nealon WH, Goodwin JS, et al. Pancreatic cancer in the general population: improvements in survival over the last decade. J Gastrointest Surg. 2006; 10(9):1212-1223; discussion 1223-1214.
36. Crane CH, Winter K, Regine WF, et al. Phase II study of bevacizumab with concurrent capecitabine and radiation followed by maintenance gemcitabine and bevacizumab for locally advanced pancreatic cancer: Radiation Therapy Oncology Group RTOG 0411. J Clin Oncol. 2009;27(25):4096-4102.
37. Loehrer PJ Sr, Feng Y, Cardenes H, et al. Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: an Eastern Cooperative Oncology Group trial. J Clin Oncol. 2011;29(31):4105-4112.